Attitudes and Experience of Women to Common Vaginal Infections

Johnson, Sarah; Griffiths, Heather; Humberstone, Fiona J.

doi:10.1097/lgt.0b013e3181d85bb7

Cited by 28 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The estimates of VVC prevalence found in this omnibus Internet survey are consistent with those found previously using a random digit dialing survey [2] and an online omnibus survey [10]. Overall, there was consistency across 5 of the 6 countries with France being the sole exception and some regional differences within countries.…”

Section: Discussionsupporting

confidence: 86%

Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States

Foxman¹,

Muraglia²,

Dietz³

et al. 2013

Journal of Lower Genital Tract Disease

234

184

View full text Add to dashboard Cite

The overall rates of VVC and RVVC were high and consistent with previous findings. Results were consistent across countries with the exception of France, which had a lower rate of VVC. This may reflect differences in risk behavior, response to infection, or sampling biases. Recurring VVC is a significant health problem in western countries, and the probability that VVC will progress to RVVC is high.

show abstract

Section: Discussionsupporting

confidence: 86%

Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States

Foxman¹,

Muraglia²,

Dietz³

et al. 2013

Journal of Lower Genital Tract Disease

234

184

View full text Add to dashboard Cite

show abstract

“…It is defined as four or more acute inflammatory episodes of VulvoVaginal Candidosis (VVC), also known as vaginal yeast infection, within a year [1,2]. The prevalence of RVVC is estimated at 6-8% in women aged between 18 and 65 years in the USA and Western Europe, according to two large studies [3,4] and similar estimates can be derived from assessments of RVVC prevalence as proportion of VVC cases and studies on population-based VVC prevalence [3-8]. …”

Section: Introductionmentioning

confidence: 99%

Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA

Aballéa

Guelfucci

Wagner

et al. 2013

Health Qual Life Outcomes

View full text Add to dashboard Cite

BackgroundRecurrent vulvovaginal candidosis (RVVC) is a chronic condition causing discomfort and pain. Health status and health-related quality of life (HRQoL) in RVVC were never previously described using validated questionnaires. The objective of this study is to describe subjective health status and HRQoL and estimate health state utilities among women with RVVC.MethodsA cross-sectional online survey was conducted among women who reported having suffered four or more yeast infections over the past 12 months, in five European countries (France, Germany, Italy, Spain and the UK) and the USA. Index scores were derived from the EQ-5D, a questionnaire providing a single index value for health status. The SF-36 questionnaire was used for HRQoL assessment. Information on disease severity, treatment patterns and productivity was also collected.Results12,834 members of online research panels were contacted. Among them, 620 women with RVVC (5%) were selected to complete the full questionnaire. The mean EQ-5D index score was 0.70 (95% confidence interval: [0.67, 0.72]) and the difference between women with a yeast infection at the time of questionnaire completion and other respondents was 0.05 (p = 0.47). The EQ-5D index score increased significantly with the time since last infection (p < 0.001). 68% of women reported depression/anxiety problems during acute episode, and 54% outside episodes, compared to less than 20% in general population (p < 0.001). All SF-36 domain scores were significantly below general population norms. Mental health domains were the most affected. The impact on productivity was estimated at 33 lost work hours per year on average, corresponding to estimated costs between €266/year and €1,130/year depending on the country.ConclusionsSubjective health status and HRQoL during and in between acute inflammatory episodes in women with RVVC are significantly worse than in the general population, despite the use of antifungal therapy. The average index score in women with RVVC is comparable to other diseases such as asthma or COPD and worse than diseases such as headache/migraine according to US and UK catalogs of index scores. The survey also revealed a significant loss of productivity associated with RVVC.

show abstract

“…It is composed of stratified squamous epithelium that contains hair follicles, sebaceous sweat glands, and apocrine glands. Vulvovaginitis is the most common gynecologic condition seen by practitioners and gynecologists [34]. The term vulvovaginitis is a broad definition that categorizes many vaginal infections as vulvovaginitis because this two conditions are interrelated.…”

Section: Discussionmentioning

confidence: 99%

Vaginal Use of Ibuprofen Isobutanolammonium (Ginenorm): Efficacy, Tolerability, and Pharmacokinetic Data: A Review of Available Data

Milani¹,

Iacobelli²

2012

ISRN Obstetrics and Gynecology

View full text Add to dashboard Cite

Vaginal infection and inflammation with or without vulvar involvement are very common gynecologicaly clinical conditions associated with morbidity and reduced quality of life. Vaginal infections are commonly treated with causal antimicrobial treatments. In addition to specific antimicrobial treatment, anti-inflammatory therapy, both systemic or topical (vaginal douche), could be useful in the integrated treatment approach of these conditions reducing symptoms and speeding up the recovery in vulvovaginitis. Ibuprofen is a well-known effective and well-tolerated anti-COX (anti-COX1 and COX2) compound. In addition, several in vitro studies suggest that Ibuprofen shares antimicrobial and antifungal activities. Ibuprofen isobutanolammonium (Ib-isb) (Ginenorm) is a soluble salt from formulation suitable for external and intravaginal use. This salt completely dissociates in aqueous solution. Ib-isob is available in sachet and vaginal douche pharmaceutical formulations. Clinical efficacy of Ib-isob has been documented in 10 clinical studies (6 controlled and 4 open trials) which have enrolled in total 399 women with vulvovaginitis. The six controlled clinical trials were performed both versus placebo (2 studies) or versus active comparators such as benzydamine. In these studied, Ib-Isb has been used in general for 7 consecutive days with a twice application daily regimen at the dose of 1 g per application. Topical application of Ib-isob induced a marked and rapid reduction in signs (erythema, oedema) and symptoms (itching and burning sensation) of vulvovaginitis. In head-to-head studies carried out in comparison with other topical products, Ib-isob induced a more rapid reduction in both subjective and objective symptoms. In particular a remarkable significant improvement of all the symptoms has been observed in the group of patients treated with Ib-isob in comparison with women receiving benzydamine. The clinical data available for Ib-isob confirm that this salt, specifically developed for gynecological use, is effective and well tolerated in vulvovaginal inflammation conditions. Efficacy of Ib-isob was greater in comparison with commonly used products. Ibuprofen-isob may be considered a useful and effective tool for the topical treatment of nonspecific vaginal diseases.

show abstract

Attitudes and Experience of Women to Common Vaginal Infections

Cited by 28 publications

References 14 publications

Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States

Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States

Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA

Vaginal Use of Ibuprofen Isobutanolammonium (Ginenorm): Efficacy, Tolerability, and Pharmacokinetic Data: A Review of Available Data

Contact Info

Product

Resources

About